Tools
Free Benzinga Pro Trial
Calendars
Trade Ideas
Short Interest
Comments
Loading...
Invesco Biotechnology & Genome ETF Stock Price, Quotes and Forecasts
PBEARCA
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Sector
Healthcare
Region
US
AUM
264.20M
Fund Score
Invesco Biotechnology & Genome ETF Price, Quotes and Forecasts | ARCA:PBE | Benzinga
Explore Invesco Biotechnology & Genome ETF stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for PBE.
| Open | - |
| High | - |
| 52 Wk High | $72.84 |
| AUM | 264.20M |
| Dividend | $0.06 |
| Ex-Div Date | Jun 24, 2024 |
| Volume | 7 |
| Market Cap | $26.28B |
| Mgmt Fee | 0.5% |
| P/E Ratio | 28.60 |
| Prev. Close | $65.49 |
| Low | - |
| 52 Wk Low | $59.32 |
| Shares Out | 4.04M |
| Yield | 0.09% |
| Div. Freq | Quarterly |
| Avg. Volume Daily | 12.08K |
| Beta | 0.81 |
| Avg. Expense Ratio | NA% |
| P/B Ratio | 3.79 |
Recent News
FAQ
Q
How do I buy Invesco Biotechnology & Genome ETF (PBE) stock?
A
You can purchase shares of Invesco Biotechnology & Genome ETF (ARCA:PBE) through any online brokerage.
Q
Who are Invesco Biotechnology & Genome ETF (PBE) competitors?
A
There are no as such competitors for Invesco Biotechnology & Genome ETF.
Q
What is the forecast, or price target, for Invesco Biotechnology & Genome ETF (PBE) stock?
A
There is no analysis for Invesco Biotechnology & Genome ETF to provide a consensus price target.
Q
What is the current price for Invesco Biotechnology & Genome ETF (PBE)?
A
The stock price for Invesco Biotechnology & Genome ETF (ARCA: PBE) is $ last updated December 31, 1969 at 7:00 PM EST.
Q
Does Invesco Biotechnology & Genome ETF (PBE) pay a dividend?
A
A quarterly cash dividend of 0.00 per share of Class A Common Stock. The quarterly cash dividend was payable on September 28, 2018 to stockholders of record on September 24, 2018.
Q
When is Invesco Biotechnology & Genome ETF (ARCA:PBE) reporting earnings?
A
Invesco Biotechnology & Genome ETF does not have any upcoming earnings scheduled.
Q
Is Invesco Biotechnology & Genome ETF (PBE) going to split?
A
There is no upcoming split for Invesco Biotechnology & Genome ETF.
| Open | - |
| High | - |
| 52 Wk High | $72.84 |
| AUM | 264.20M |
| Dividend | $0.06 |
| Ex-Div Date | Jun 24, 2024 |
| Volume | 7 |
| Market Cap | $26.28B |
| Mgmt Fee | 0.5% |
| P/E Ratio | 28.60 |
| Prev. Close | $65.49 |
| Low | - |
| 52 Wk Low | $59.32 |
| Shares Out | 4.04M |
| Yield | 0.09% |
| Div. Freq | Quarterly |
| Avg. Volume Daily | 12.08K |
| Beta | 0.81 |
| Avg. Expense Ratio | NA% |
| P/B Ratio | 3.79 |
About Invesco Capital Management LLC
Sector
N/A
Industry
N/A
ETF Details
| Sector | Healthcare |
| Category | High Performer-Mid Growth |
| Investment Style | Mid Cap Growth |
| Fund Inception | Jun 23, 2005 |
| Managers | Tony Seisser Pratik Doshi Peter Hubbard Michael Jeanette |
| Definition | This Equity Fund Portfolio contains majority of stocks with strong financial performance and average growth potential |
Investment Policy
The Fund generally will invest at least 90% of its total assets in securities that comprise the Underlying Index. The Underlying Index is composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, and are companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| GILD | Gilead Sciences Inc | 5.48% |
| ILMN | Illumina Inc - Common | 5.37% |
| INCY | Incyte Corp. | 5.32% |
| BMRN | Biomarin Pharmaceutica... | 5.09% |
| VRTX | Vertex Pharmaceuticals... | 5.05% |
| AMGN | Amgen Inc. | 4.98% |
| REGN | Regeneron Pharmaceutic... | 4.97% |
| NBIX | Neurocrine Biosciences... | 4.51% |
| IONS | Ionis Pharmaceuticals ... | 3.24% |
| HALO | Halozyme Therapeutics ... | 3.17% |
Popular Channels
Tools & Features
Partners & Contributors
About Benzinga
© 2025 Benzinga | All Rights Reserved